Roche/Chugai’s Hemlibra wins green light for bleeding disorder
The European Commission has licensed Roche/Chugai’s Hemlibra for the routine prevention of bleeding episodes in patients with haemophilia A with factor VIII inhibitors.
Read More
Tag: BPA
Roche’s haemophilia drug cut bleeds by 87 percent in trial
Roche has presented a new batch of data showing that its experimental bispecific monoclonal antibody emicizumab significantly reduced bleeds in patients with haemophilia A and inhibitors to factor VIII.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
